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ThermoregulationAbstract Background: Shivering associated with spinal anesthesia is a common and uncomfort-
able problem and may interfere with monitoring, oxygen consumption and carbon dioxide produc-
tion. The aim of the study was to evaluate the effect of intrathecal nalbuphine on the prevention of
shivering during spinal anesthesia in patients undergoing knee arthroscopy.
Methods: 60 patients (ASA physical status I or II) scheduled for knee arthroscopy under spinal
anesthesia were randomly assigned to one of two equal groups: Group C (control group,
n= 30) receiving 2.5 ml of 0.5% bupivacaine during spinal anesthesia; and Group N patients (nal-
buphine group, n= 30) receiving 2.5 ml of a mixture of 400 lg nalbuphine plus 0.5% bupivacaine
during spinal anesthesia. Before commencing regional anesthesia, standard monitoring was estab-
lished and patients were given intravenous 15 ml/kg/h of crystalloid solution (at room temperature
23–25 C). All operations were performed in the same operating room which maintained at a con-
stant temperature of 23–25 C and no means of active warming were used. Mean arterial blood
pressure (MAP), heart rate (HR), arterial oxygen saturation (SPO2), core (tympanic) temperature,
the incidence and severity of shivering were all determined and recorded at baseline and every
10 min after anesthesia till end of surgery.
Results: Shivering was observed in 19 patients (63.3%) in control group and 7 patients in nalbuphine
group (23.3%) with significant difference between the two groups (P= 0.004) and significant differ-
ence in intensity of shivering and core temperature (P< 0.001). No significant statistical difference
was observed as regards hemodynamic parameters and oxygen saturation between the two groups.
Conclusion: Intrathecal nalbuphine is an effective and safemethod to prevent shivering during spinal
anesthesia in patients undergoing knee arthroscopy.
 2016 Publishing services by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Shivering is a common post-operative event, defined as an
involuntary, repetitive activity of one or more skeletal muscles.
The incidence of shivering has been found to be high, approx-
imately 40–50% in different studies [1]. Postanesthetic
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as an increase in oxygen consumption, carbon dioxide
production, catecholamine release, cardiac output, intraocular
pressure and complications such as tachycardia and hyperten-
sion. In addition to this, shivering may inhibit accurate
monitoring by causing artifacts in the monitor [2–5]. Shivering
also increases intracranial pressure, and may contribute to
increased wound pain, delayed wound healing, and delayed
discharge from post-anesthetic care [6,7].
The treatment of shivering includes both pharmacological
and non-pharmacological methods. The non-pharmacological
management is by external heating like the use of forced air
warming, warming blankets, and warmed fluids. According
to the results of a meta-analysis, the most frequently reported
pharmacological interventions include clonidine, pethidine,
tramadol, nefopam and ketamine [8]. Unfortunately, no gold
standard treatment is known for shivering as the administra-
tion of all the available drugs is associated with various adverse
effects.
Nalbuphine is a lipophilic semi-synthetic opioid related to
both oxymorphone and naloxone, and it has relatively
potent l-antagonist and j-agonist activities. Because of its
j-antagonist properties, nalbuphine should produce fewer
l-mediated side effects such as respiratory depression, pruritus,
nausea and vomiting [9]. It has a high affinity for j-opioid
receptors in the central nervous system. Theoretically,
nalbuphine may have a significant effect on postanesthetic shiv-
ering [9]. Intrathecal nalbuphine was widely used for postoper-
ative analgesia in many studies [9,10].
The present study designed to study the effect of intrathecal
nalbuphine on prevention of postspinal shivering in patients
undergoing knee arthroscopy.
2. Materials and methods
This study was performed between January 2013 and August
2013 after approval of ethical committee of Faculty of Medi-
cine, Menoufiya University and Pan African Clinical Trial
Registry (www.pactr.org) PACTR 201505001091143. In a
prospective, controlled, randomized clinical trial, after receiv-
ing written consent from patients, 60 patients, 20–60 years of
both sex and American Society of Anesthesia (ASA) physical
status I or II scheduled for knee arthroscopy under spinal
anesthesia were enrolled. Patients with contraindications to
regional anesthesia, allergy to the study medication, and obese
with body mass index (BMI) >30 were excluded. Patients were
randomly assigned to one of two groups through closed
envelop technique. Group C (control group, n= 30). Group
N (nalbuphine group, n= 30). Before commencing regional
anesthesia, standard monitoring was established and patients
were given intravenous 15 ml/kg/h of crystalloid solution (at
room temperature 23–25 C) through an 18-gauge peripheral
venous catheter. Oxygen 5 L/min was administered through
a mask during anesthesia and patients were covered with
drapes but not actively warmed. Spinal anesthesia was per-
formed in the setting position at the L3–4 or L4–L5 levels,
midline approach by 25-gauge Quinkle needle using 2.5 ml
hyperbaric bupivacaine, 5 mg/ml in group C and 2.5 ml of a
mixture of 400 lg nalbuphine plus hyperbaric bupivacaine,
5 mg/ml. After the procedure, patients were positioned supine.
Sensory levels were determined by pinprick and the motorblockade was evaluated using Bromage’s criteria. All opera-
tions were performed in the same operating room which main-
tained at a constant temperature of 23–25 C and no means of
active warming were used. The mean arterial pressure (MAP),
heart rate (HR), arterial oxygen saturation (Spo2), and core
(tympanic) temperature were measured and recorded preoper-
ative then every 10 min till the end of surgery. The incidence
and severity of shivering were recorded during the operation
and in the recovery room. Shivering was graded with a scale
described by Bedside Shivering Assessment Score (BSAS) as
follows [11]:
1. None: no shivering noted on palpation of the masseter,
neck, or chest wall.
2. Mild: shivering localized to the neck and/or thorax only.
3. Moderate: shivering involves gross movement of the upper
extremities (in addition to neck and thorax).
4. Severe: shivering involves gross movements of the trunk
and upper and lower extremities.
Also any complications were recorded for example
hypotension was defined as a decrease in the (MBP) to less
20% than the baseline value, which was treated with incre-
ments 5–10 mg of intravenous ephedrine. Bradycardia was
defined as a decrease in HR less than 50 b/min which was trea-
ted with 0.5 mg IV atropine.
2.1. Statistical analysis
A power analysis was performed using a power of 90% and an
a value 0.05. From previous clinical studies, we assumed that
the incidence of shivering would be 20% in the nalbuphine
group after premedication and 60% in the placebo group after
premedication with a standard deviation 40. The sample size
was calculated to be 29 patients so we decided to include 30
patients in each group in the study. We used Power and Sample
size statistics program (PS version 3.0.43) for power analysis.
The collected data were analyzed by Statistical Package for
Social Science (SPSS) version 16. Parametric data were
expressed as mean ± SD. The comparison of the mean ± SD
of two groups was done using the paired and unpaired Student’s
t test. Nonparametric data were expressed as number and per-
centage of the total number of patients. Determining the extent
of a single observed series of proportions, difference from a the-
oretical or expected distribution was done using the Chi square
test. P-value <0.05 was considered statistically significant.
3. Results
The demographic data including age, sex, weight, height and
the duration of surgery (Table 1) were comparable between
both groups. The mean arterial blood pressure decreased in
both groups from the baseline measurements with insignificant
difference between the two groups (Table 2). As well as the
heart rate decreased from the baseline with insignificant differ-
ence between the studied groups (Table 3). The number of
patients receiving vasoactive agents was comparable between
the two groups (6 vs 5). Three of eight patients in group C
received ephedrine, two received atropine and one received
both atropine and ephedrine. Three of the five patients in
group N received ephedrine and two received atropine.
Table 1 Demographic data and duration of surgery.
Group C
(n= 30)
Group N
(n= 30)
P-value
Age (Years) 47.67 ± 7.68 45.47 ± 7.35 0.262
Sex (F/M) 12/18 9/21 0.588
Height (Cm) 165.63 ± 9.07 167.83 ± 9.12 0.353
Weight (kg) 89.17 ± 10.79 88.27 ± 10.67 0.746
Duration of
surgery (Min)
43.76 ± 6.75 45.72 ± 7.38 0.288
Group C: control group, Group N: nalbuphine group. Data were
presented as Mean ± SD, number of patients.
Table 2 Mean arterial blood pressure.
Group C (n= 30) Group N (n= 30) P-value
Baseline 95.92 ± 8.11 94.88 ± 10.42 0.668
10 min 93 ± 6.89 91.08 ± 6.93 0.286
20 min 92.4 ± 7.97 90.56 ± 5.32 0.297
30 min 88.96 ± 8 89.87 ± 6.54 0.631
40 min 90.27 ± 4.26 90.23 ± 4.36 0.971
50 min 92.27 ± 6.82 91.76 ± 6.57 0.769
Group C: control group, Group N: nalbuphine group. Data were
presented as Mean ± SD.
* P< 0.05 significant between the two groups.
Table 3 Heart rate.
Group C (n= 30) Group N (n= 30) P-value
Baseline 82.1 ± 8.53 81.23 ± 8.21 0.689
10 min 79.97 ± 9.24 79.33 ± 8.32 0.779
20 min 77.53 ± 10.08 77.6 ± 8.43 0.977
30 min 76.67 ± 9.26 75.82 ± 9.23 0.723
40 min 76.37 ± 6.16 75.48 ± 8.14 0.635
50 min 77.87 ± 8.15 76.83 ± 7.74 0.614
Group C: control group, Group N: nalbuphine group. Data were
presented as Mean ± SD.
* P< 0.05 significant between the two groups.
Table 4 Core temperature.
Group C (n= 30) Group N (n= 30) P-value
Baseline 37.03 ± 0.16 37.13 ± 0.15 0.015
10 min 36.9 ± 0.12 37.05 ± 0.17* <0.001
20 min 35.94 ± 0.17 36.8 ± 0.12* <0.001
30 min 35.33 ± 0.23 36.73 ± 0.11* <0.001
40 min 35.51 ± 0.18 36.72 ± 0.11* <0.001
50 min 35.69 ± 0.24 36.73 ± 0.12* <0.001
Group C: control group, Group N: nalbuphine group. Data were
presented as Mean ± SD.
* P< 0.05 significant between the two groups.
Table 5 Postanesthetic shivering.
Group C
(n= 30)
Group N
(n= 30)
P-value
Shivering score
0 11(36.7%) 23(76.7%)* 0.019
1 9(30%) 3(10%) 0.107
2 7(23.3%) 4(13.3%) 0.505
3 3(10%) 0(0%) 0.237
Incidence of shivering 19(63.3%) 7(23.3)* 0.004
Group C: control group, Group N: nalbuphine group. Data were
presented as number of patients (%), Mean ± SD.
* P< 0.05 significant between the two groups.
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with significant lower values (P< 0.001) in nalbuphine group
when compared to control group (Table 4). As regards the
incidence of shivering (Table 5) was significantly less in nal-
buphine group (7 of 30) versus 19 of 30 in control group(P= 0.019). SPO2 exceeded 95% in all patients at all the study
times with insignificant difference between the two groups.
4. Discussion
The present study showed that adding a small dose (400 lg) of
nalbuphine to the intrathecal bupivacaine during anesthesia
for knee arthroscopy reduces the incidence and severity of
shivering without hemodynamic effects.
Shivering associated with neuraxial anesthesia is a common
and uncomfortable side effect. It develops in up to 60% of
patients. The mechanism of shivering during regional anesthe-
sia has not been fully understood. Postanesthesia shivering is
probably due to redistribution of heat from core to periphery,
loss of thermoregulatory vasoconstriction below the level of
blockade resulting in an increased heat loss from body surfaces
[12,13], and altered thermoregulation characterized by a
decrease in vasoconstriction threshold [14]. Shivering causes
patient distress and also leads to other adverse effects, includ-
ing increased oxygen consumption, carbon dioxide, lactic acid
production and increased left ventricular systolic work index
[15,16]. Prevention seems essential especially in vulnerable
patients and should be effective, simple, and cheap. IV drugs
are the ‘‘gold standard” for the treatment of postoperative
shivering [17]. Although IV nalbuphine has long been used
for the treatment of postanesthetic shivering [16–18], it is gen-
erally administered to treat shivering that has already begun.
As compared with its use in treatment, its use in prevention
of shivering has not been well investigated especially its
intrathecal route of administration. Nalbuphine, a semisyn-
thetic opioid related to both naloxone and oxymorphone,
has the characteristics of l-antagonist and j-agonist activities
[9,18]. It has a high affinity for j-opioid receptors in the central
nervous system [18], through which, it exerts its possible
antishivering mechanisms. As suggested by many studies,
j-opioid receptors may play a more important role than
l-opioid receptors in the treatment of postspinal shivering
[18,19].
In this study, the significant reduced incidence of shivering
with intrathecal nalbuphine versus placebo (p< 0.05) is
similar to that reported by Roy and colleagues who found sim-
ilar effects of intrathecal meperidine [20], and by Tiwari et al.
[10]. Also, this is comparable with the studies used nalbuphine
intravenously to control postoperative shivering [18,21].
The core temperature was also, significantly decreased in
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studies [20–23]. The insignificant change in the mean arterial
blood pressure documented in the study is in accordance with
other studies that used intrathecal nalbuphine as Roy and col-
leagues [20], Fournier and co-workers [9], Tiwari et al. [10],
and Chaney [24].
5. Conclusion
In conclusion, intrathecal nalbuphine, a j-receptor agonist,
provides a safe and effective prevention of postspinal shivering
in patients undergoing knee arthroscopy.
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